While underreported, ADR data offers significant value to the drug development value chain to refine the predictive capability and stability, and provide enhanced patient safety.
Philipp Hofmann, MD
Advertisement
Director, Pharmacovigilance & QPPV, Navitas Life Sciences
Articles by Philipp Hofmann, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI in Action: Breaking Down Clinical Trial Bottlenecks
2
Unlocking the Potential of Agentic AI to Reduce Trial Delays
3
Balancing Human Oversight and Automation in AI-Driven Trials
4
2025 SCRS Global Site Solutions Summit: How Standardized CDAs Can Accelerate Site Activation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
